modelGlucosamine
Extends from Pharmacolibrary.Drugs.ATC.M.M01AX05.
Information
| name: | Glucosamine | |
| ATC code: | M01AX05 | route: | oral |
| compartments: | 1 | |
| dosage: | 1500 | mg |
| volume of distribution: | 2.1 | L |
| clearance: | 0.29 | L/h/kg |
| other parameters in model implementation | ||
Glucosamine is an amino sugar and a prominent precursor in the biochemical synthesis of glycosylated proteins and lipids. It is most commonly used as a dietary supplement for the treatment and management of osteoarthritis and joint pain. Glucosamine is not officially approved by the FDA for prescription use and is widely available as an over-the-counter supplement.
Pharmacokinetics
Pharmacokinetic parameters were reported for healthy adult volunteers (both male and female), following single oral administration of glucosamine sulfate. Parameters were typically derived from single-dose administration studies in healthy adults aged between 18 and 60 years.
References
Barclay, TS, et al., & McCart, GM (1998). Glucosamine. The Annals of pharmacotherapy 32(5) 574–579. DOI:10.1345/aph.17235 PUBMED:https://pubmed.ncbi.nlm.nih.gov/9606479
Johnsen, M, et al., & Müller, RU (2016). Oral Supplementation of Glucosamine Fails to Alleviate Acute Kidney Injury in Renal Ischemia-Reperfusion Damage. PloS one 11(8) e0161315–None. DOI:10.1371/journal.pone.0161315 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27557097
Agiba, AM, et al., & Geneidi, AS (2018). Geriatric-Oriented High Dose Nutraceutical ODTs: Formulation and Physicomechanical Characterization. Current drug delivery 15(2) 267–277. DOI:10.2174/1567201814666170320143824 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28322163
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
| Pharmacolibrary.Types.TransferRate | ka (from PK_1C_enteral) | 0.016666666666666666 | first order absorption rate |
| Modelica.Units.SI.Time | Tlag (from PK_1C_enteral) | 600 | delay between oral administration and absorption (default 10min) |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)